Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
HOOKIPA Pharma Inc. HOOK
$2.00
+$0.13 (6.38%)
На 18:01, 12 мая 2023
+50.00%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
106951277.00000000
-
week52high
2.01
-
week52low
0.68
-
Revenue
14249000
-
P/E TTM
-2
-
Beta
0.81899800
-
EPS
-1.09000000
-
Last Dividend
0.00000000
-
Next Earnings Date
15 мая 2023 г. в 12:30
Описание компании
HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in Phase I/II clinical trial for the treatment of human papillomavirus 16-positive cancers. The company's preclinical stage products include HB-300 program for prostate cancer; and HB-700 for targeting mutated KRAS in pancreatic, colorectal, and lung cancer. HOOKIPA Pharma Inc. has a collaboration with Gilead Sciences, Inc. to collaborate on preclinical research programs to evaluate potential vaccine products using or incorporating its replicating and non-replicating technology platforms for the treatment, cure, diagnosis, or prevention of Hepatitis B Virus. The company was incorporated in 2011 and is headquartered in New York, New York.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Truist Securities | Buy | Buy | 23 авг 2022 г. |
| SVB Leerink | Outperform | Outperform | 11 авг 2022 г. |
| RBC Capital | Outperform | Outperform | 25 мар 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 17 февр 2022 г. |
| SVB Leerink | Outperform | Outperform | 16 февр 2022 г. |
| RBC Capital | Outperform | Outperform | 15 ноя 2022 г. |
| B of A Securities | Underperform | Buy | 02 дек 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Reilly Timothy P. | A | 40000 | 40000 | 30 июн 2022 г. |
| van de Winkel Jan | A | 40000 | 40000 | 30 июн 2022 г. |
| Orlinger Klaus | A | 48350 | 48350 | 30 июн 2022 г. |
| Necina Roman | A | 48350 | 48350 | 30 июн 2022 г. |
| O'Neill Julie | A | 20000 | 20000 | 30 июн 2022 г. |
| Matushansky Igor | A | 92950 | 92950 | 30 июн 2022 г. |
| Kelly Michael Aaron | A | 20000 | 20000 | 30 июн 2022 г. |
| Kaufman David Ross | A | 20000 | 20000 | 30 июн 2022 г. |
| Aldag Jorn | A | 275250 | 275250 | 30 июн 2022 г. |
| Baker Christine D. | A | 100000 | 100000 | 30 июн 2022 г. |
Новостная лента
HOOKIPA Pharma Inc. (HOOK) Reports Q1 Loss, Lags Revenue Estimates
Zacks Investment Research
11 мая 2023 г. в 09:56
HOOKIPA Pharma Inc. (HOOK) came out with a quarterly loss of $0.27 per share versus the Zacks Consensus Estimate of a loss of $0.24. This compares to loss of $0.40 per share a year ago.
HOOKIPA Pharma to Participate in Upcoming Investor Conferences in May
GlobeNewsWire
04 мая 2023 г. в 07:02
NEW YORK and VIENNA, Austria, May 04, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that HOOKIPA's management team will participate in and present at the following upcoming investor conferences:
HOOKIPA Pharma to Report First Quarter 2023 Financial Results and Recent Business Highlights on May 11, 2023
GlobeNewsWire
04 мая 2023 г. в 07:01
NEW YORK and VIENNA, Austria, May 04, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that it will release its first quarter 2023 financial results and business highlights on May 11, 2023.
HOOKIPA to Present a Trial in Progress Poster on its Prostate Cancer Phase 1/2 Clinical Trial at ASCO
GlobeNewsWire
26 апр 2023 г. в 11:30
NEW YORK and VIENNA, Austria, April 26, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that a Trial in Progress poster on its ongoing Phase 1/2 clinical study (NCT05553639) of HB-300 in prostate cancer has been accepted for presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place June 2-6, 2023.
HOOKIPA Pharma Inc. (HOOK) Q4 2022 Earnings Call Transcript
Seeking Alpha
15 мар 2023 г. в 12:47
HOOKIPA Pharma Inc. (NASDAQ:HOOK ) Q4 2022 Results Conference Call March 15, 2023 8:30 AM ET Company Participants Matthew Beck - Executive Director, Investor Relations Joern Aldag - Chief Executive Officer Reinhard Kandera - Chief Financial Officer Katia Schlienger - Chief Medical Officer Conference Call Participants Alec Stranahan - Bank of America Arthur He - H. C. Wainwright Asthika Goonewardene - Truist Securities Roy Buchanan - JMP Securities Suzanne van Voorthuizen - Kempen Operator Good morning and thank you for joining the HOOKIPA Pharma Fourth Quarter and Full Year 2022 Earnings and 2022 Outlook Conference Call.